

# Bengt Hallberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8154067/publications.pdf>

Version: 2024-02-01

44  
papers

3,214  
citations

236925

25  
h-index

265206

42  
g-index

45  
all docs

45  
docs citations

45  
times ranked

3875  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. <i>JCO Precision Oncology</i> , 2022, 6, e2100271.	3.0	8
2	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of <i>ALK</i> mutation. <i>EMBO Journal</i> , 2021, 40, e105784.	7.8	35
3	Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells. <i>Cancers</i> , 2021, 13, 1909.	3.7	6
4	Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. <i>Cell Reports</i> , 2021, 36, 109363.	6.4	9
5	Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate. <i>BMC Cancer</i> , 2021, 21, 950.	2.6	4
6	BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells. <i>Journal of Molecular Biology</i> , 2021, 433, 167158.	4.2	9
7	Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future. <i>Cancers</i> , 2021, 13, 5897.	3.7	13
8	ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. <i>Nature Communications</i> , 2021, 12, 6813.	12.8	21
9	Analysis of <i>ALK</i> , <i>MYCN</i> , and the ALK ligand <i>ALKAL2</i> ( <i>FAM150B/AUG1±</i> ) in neuroblastoma patient samples with chromosome arm 2p rearrangements. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 50-57.	2.8	18
10	11q Deletion or ALK Activity Curbs DLC2 Expression to Maintain an Undifferentiated State in Neuroblastoma. <i>Cell Reports</i> , 2020, 32, 108171.	6.4	25
11	The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. <i>Scientific Reports</i> , 2020, 10, 218.	3.3	20
12	Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. <i>Frontiers in Oncology</i> , 2019, 9, 579.	2.8	24
13	Targeting anaplastic lymphoma kinase in neuroblastoma. <i>Apmis</i> , 2019, 127, 288-302.	2.0	53
14	Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. <i>Scientific Reports</i> , 2019, 9, 19353.	3.3	19
15	Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. <i>Science Signaling</i> , 2018, 11, .	3.6	36
16	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002550.	1.2	47
17	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. <i>Science Signaling</i> , 2017, 10, .	3.6	41
18	Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation. <i>Cancers</i> , 2017, 9, 149.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent. <i>Oncotarget</i> , 2017, 8, 11566-11578.	1.8	16
20	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 941-52.	2.4	62
21	Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, <i>Drosophila</i> and mice. <i>Oncotarget</i> , 2016, 7, 29011-29022.	1.8	51
22	Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism. <i>PLoS ONE</i> , 2015, 10, e0123542.	2.5	24
23	FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. <i>ELife</i> , 2015, 4, e09811.	6.0	123
24	The ALK Receptor Family. , 2015, , 1-51.		0
25	Intragenic anaplastic lymphoma kinase ( <i>ALK</i> ) rearrangements: Translocations as a novel mechanism of <i>ALK</i> activation in neuroblastoma tumors. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 99-109.	2.8	45
26	The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. <i>Science Signaling</i> , 2014, 7, ra102.	3.6	80
27	Phosphoproteomic analysis of anaplastic lymphoma kinase ( <i>ALK</i> ) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated <i>ALK</i> in neuroblastoma cells. <i>FEBS Journal</i> , 2013, 280, 5269-5282.	4.7	35
28	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. <i>Nature Reviews Cancer</i> , 2013, 13, 685-700.	28.4	538
29	Cell culture and <i>Drosophila</i> model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 373-82.	2.4	59
30	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. <i>Cancer Cell</i> , 2012, 22, 117-130.	16.8	270
31	Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment. <i>PLoS ONE</i> , 2012, 7, e33581.	2.5	27
32	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy. <i>Cancer Research</i> , 2011, 71, 98-105.	0.9	80
33	Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. <i>Biochemical Journal</i> , 2011, 440, 405-414.	3.7	77
34	ALK and NSCLC: Targeted therapy with ALK inhibitors. <i>F1000 Medicine Reports</i> , 2011, 3, 21.	2.9	23
35	Anaplastic lymphoma kinase: signalling in development and disease. <i>Biochemical Journal</i> , 2009, 420, 345-361.	3.7	375
36	The ligand Jelly Belly (Jeb) activates the <i>Drosophila</i> Alk RTK to drive PC12 cell differentiation, but is unable to activate the Mouse ALK RTK. <i>Journal of Experimental Zoology Part B: Molecular and Developmental Evolution</i> , 2007, 308B, 269-282.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Characterization of the expression of the ALK receptor tyrosine kinase in mice. <i>Gene Expression Patterns</i> , 2006, 6, 448-461.	0.8	142
38	Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. <i>Nature</i> , 2003, 425, 512-516.	27.8	151
39	Exoenzyme T of <i>Pseudomonas aeruginosa</i> elicits cytotoxicity without interfering with Ras signal transduction. <i>Cellular Microbiology</i> , 2001, 3, 237-246.	2.1	49
40	14-3-3 proteins are required for the inhibition of Ras by exoenzyme S. <i>Biochemical Journal</i> , 2000, 349, 697-701.	3.7	30
41	Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase. <i>Oncogene</i> , 1998, 17, 691-697.	5.9	48
42	Calcium/calmodulin inhibition of basic-helix-loop-helix transcription factor domains. <i>Nature</i> , 1994, 368, 760-764.	27.8	165
43	The activation of phosphatidylinositol 3-kinase by Ras. <i>Current Biology</i> , 1994, 4, 798-806.	3.9	303
44	11q Deletion or ALK Activity Curbs DLC2 Expression to Maintain an Undifferentiated State in Neuroblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0